Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease

Unmet needs in the treatment of psoriasis call for novel therapeutic strategies. Pustular psoriasis and psoriatic arthritis often represent a therapeutic challenge. Focus on IL-36 cytokines offers an interesting approach, as the IL-36 axis has been appointed a critical driver of the autoinflammatory responses involved in pustular psoriasis. Two IL-36R blocking antibodies, imsidolimab and spesolimab, are currently undergoing phase II and III clinical trials, with promising results.

Automated summary

Unmet needs in the treatment of psoriasis require novel therapeutic strategies. Focus on IL-36 cytokines as a critical driver of autoinflammatory responses in pustular psoriasis has led to promising results in clinical trials of two IL-36R blocking antibodies, imsidolimab and spesolimab.